Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12192433 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KMT2ASLC6A3SLC6A4RAB9A | |
| SCHEMBL2313544 | 0.85 | TTR (0.51) | KMT2ARAB9ATTRNPC1HSD17B10 | |
| SCHEMBL2500109 | 0.84 | RAB9A (0.44) | ALDH1A1KMT2ASLC6A3SLC6A4RAB9A | |
| SCHEMBL12388490 | 0.84 | KDM4C (0.48) | KMT2ARAB9ALMNAMAPK1HTT | |
| SCHEMBL30949650 | 0.82 | CYP46A1 (0.55) | ALDH1A1KMT2ASLC6A3SLC6A4RAB9A | |
| SCHEMBL2313719 | 0.82 | KDM4E (0.52) | ALDH1A1KMT2ARAB9ALMNAMAPK1 | |
| SCHEMBL1569116 | 0.82 | EGFR (0.57) | ALDH1A1KMT2ASLC6A3SLC6A4LMNA | |
| SCHEMBL27324419 | 0.81 | SLC6A3 (0.65) | ALDH1A1KMT2ASLC6A3SLC6A4RAB9A | |
| SCHEMBL30876354 | 0.81 | SLC6A3 (0.65) | ALDH1A1KMT2ASLC6A3SLC6A4RAB9A | |
| SCHEMBL29706660 | 0.81 | GAA (0.50) | ALDH1A1KMT2ASLC6A3SLC6A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748462-B2 | Spirocyclic GPR40 modulators | AMGEN INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2358656-B1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2358656-B1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010045258-A2 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111056-A1 | CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ALDH1A1 1149/4885KMT2A 3040/4885SLC6A3 2611/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | ALDH1A1 309/4885KMT2A 2883/4885SLC6A3 2642/4885 |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | ALDH1A1 1173/4885KMT2A 4216/4885SLC6A3 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.